interferon - for COVID-19   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.16 [0.96, 1.40]< 10%1 study (1/-)5.8 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 3.41 [1.33, 8.73]> 10%1 study (1/-)99.5 %some concernnot evaluable moderateimportant-
death or ventilation 1.05 [0.90, 1.23]< 10%1 study (1/-)27.2 %some concernnot evaluable moderateimportant-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1/-)92.4 %some concernnot evaluable moderateimportant-
ventilation 0.29 [0.05, 1.56]< 10%1 study (1/-)92.5 %some concernnot evaluable moderateimportant-
ICU admission 0.37 [0.14, 1.00]< 10%1 study (1/-)97.5 %some concernnot evaluable moderatenon important-

-- safety endpoints 00

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 95, 91, 90